Veralto names Kimberly Chainey as Chief Legal Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
New Appointment: Veralto (VLTO) has appointed Kimberly Chainey as Senior Vice President and Chief Legal Officer, effective December 1, 2025.
Previous Experience: Chainey previously served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Aptar Group (ATR), where she managed global legal affairs.
Leadership Role: In her new role, Chainey will report directly to Veralto President and CEO, Jennifer L. Honeycutt.
Extensive Background: With over 20 years of experience, Chainey has advised C-suite executives and boards, focusing on complex legal, regulatory, compliance, and government relations challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATR
Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is 148.00 USD with a low forecast of 133.00 USD and a high forecast of 172.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 123.850
Low
133.00
Averages
148.00
High
172.00
Current: 123.850
Low
133.00
Averages
148.00
High
172.00
About ATR
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aptar Achieves Prestigious 'A' Score on CDP Climate Change Assessment for Second Year
- Climate Leadership: Aptar has secured an 'A' score from CDP for the second consecutive year, reflecting its ongoing commitment to emission reductions and climate risk management, thereby reinforcing its leadership in drug delivery and consumer products.
- Emission Reduction Targets: The company has established science-based targets aimed at limiting greenhouse gas emissions to align with the 1.5°C goal by 2030, demonstrating a strong commitment to sustainability supported by renewable energy purchase agreements.
- Transparency and Accountability: Aptar's improvements in climate-related financial disclosures, in line with TCFD requirements, enhance its transparency and accountability in the global market, which is crucial for attracting investor interest in its sustainability initiatives.
- Industry Impact: With over 22,000 companies disclosing environmental data through CDP in 2025, Aptar ranks in the top 4%, which not only boosts its brand image but also provides substantial support for its competitive position in the global market.
Continue Reading
AptarGroup Supports CastleVax's Phase II Clinical Trial of COVID-19 Vaccine with Innovative Delivery Solutions
- Vaccine Delivery Innovation: AptarGroup's LuerVax® and Spray Divider™ are utilized in CastleVax's Phase II clinical trial of CVAX-01, underscoring the company's ongoing commitment to advancing vaccine delivery technologies, which is expected to enhance the effectiveness and convenience of vaccination.
- Clinical Trial Scale: The trial will follow approximately 200 U.S. adults, including high-risk individuals and those over 65, for six months to assess the safety and immune response of the nasal vaccine, potentially providing critical data for future vaccine development.
- Technical Support Advantage: By offering comprehensive regulatory guidance and technical support, Aptar helps customers navigate complexities, thereby accelerating the delivery of life-changing therapies, further solidifying its leadership in nasal vaccine delivery systems.
- Market Impact: Aptar's expertise and innovative design capabilities position it as the preferred partner for pharmaceutical collaborators, driving the development of next-generation medicines and significantly enhancing the company's competitiveness in the global drug delivery market.
Continue Reading